HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

This study is testing a new drug called HRS-4642, combined with standard chemotherapy (gemcitabine and nab-paclitaxel), as a treatment before surgery for people with pancreatic cancer that may be removable or is on the borderline of being removable. **You may be eligible if...** - You are 18–80 years old - You have been diagnosed with pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) - Your cancer is considered resectable or borderline resectable based on imaging - You are in reasonably good health and able to carry out daily activities - You have at least one measurable tumor on imaging **You may NOT be eligible if...** - Your cancer has spread to distant parts of the body - You have severe heart, liver, or kidney problems - You are pregnant or unwilling to use contraception during the study Talk to your doctor to see if this trial is right for you.